DALN vs CMMB Comparison

DallasNews Corp is a local news and information publishing company. It operates The Dallas Morning News (dallasnews.com), Texas' newspaper. These operations generate revenue from advertising sales within the company's newspaper and digital platforms, subscriptions and retail sales of its newspaper, and commercial printing and distribution services predominantly related to national newspapers. In addition to traditional print and digital advertising, the company has a full-service agency, Medium Giant, offering businesses comprehensive, strategic, and creative marketing solutions. The company's two reportable segments are TDMN and Agency. Maximum revenue is derived from the TDMN segment, which comprises its traditional print business. The firm's customer base is concentrated in North Texas.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.